MIRM
Mirum Pharmaceuticals Inc

1,637
Mkt Cap
$5.47B
Volume
505,558.00
52W High
$109.28
52W Low
$36.88
PE Ratio
-189.63
MIRM Fundamentals
Price
$90.66
Prev Close
$89.78
Open
$90.13
50D MA
$94.64
Beta
0.79
Avg. Volume
733,192.96
EPS (Annual)
-$0.4654
P/B
14.95
Rev/Employee
$1.4M
$3,901.29
Loading...
Loading...
News
all
press releases
Eventide Asset Management LLC Sells 114,922 Shares of Mirum Pharmaceuticals, Inc. $MIRM
Eventide Asset Management LLC cut its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 4.4% in the third quarter, according to the company in its most recent disclosure with the...
MarketBeat·9h ago
News Placeholder
More News
News Placeholder
Mirum Pharmaceuticals, Inc. $MIRM Stock Holdings Reduced by Boone Capital Management LLC
Boone Capital Management LLC reduced its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 16.5% during the 3rd quarter, according to the company in its most recent filing with...
MarketBeat·12h ago
News Placeholder
Mirum Pharmaceuticals, Inc. $MIRM Shares Bought by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. grew its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 17.0% in the 3rd quarter, according to the company in its most recent...
MarketBeat·3d ago
News Placeholder
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on March 11, 2026, the Compensation Committee of Mirums Board of Directors granted inducement awards...
Business Wire·3d ago
News Placeholder
Teachers Retirement System of The State of Kentucky Invests $1.08 Million in Mirum Pharmaceuticals, Inc. $MIRM
Teachers Retirement System of The State of Kentucky acquired a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the third quarter, according to the company in its most recent...
MarketBeat·8d ago
News Placeholder
Mirum Completes Enrollment & Screening in Liver Disease Studies
MIRM completes enrollment in phase III AZURE-1 and screening in AZURE-4 for brelovitug in HDV, with top-line data expected in the second half of 2026.
Zacks·9d ago
News Placeholder
TD Asset Management Inc Buys Shares of 15,400 Mirum Pharmaceuticals, Inc. $MIRM
TD Asset Management Inc acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities...
MarketBeat·9d ago
News Placeholder
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced completion of enrollment in the Phase 3 AZURE-1 study and completion of screening in the Phase 3 AZURE-4...
Business Wire·10d ago
News Placeholder
William Blair Investment Management LLC Acquires Shares of 313,259 Mirum Pharmaceuticals, Inc. $MIRM
William Blair Investment Management LLC bought a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 3rd quarter, according to its most recent disclosure with the...
MarketBeat·12d ago
News Placeholder
Vanguard Group Inc. Sells 19,500 Shares of Mirum Pharmaceuticals, Inc. $MIRM
Vanguard Group Inc. decreased its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 0.8% during the 3rd quarter, according to its most recent filing with the Securities and...
MarketBeat·12d ago
<
1
2
...
>

Latest MIRM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.